This data confirm a previous study performed in mouse ovarian carcinomas, where agonistic anti-CD137 mAb augmented the impact of anti-PD-1 + anti-CTLA-4 mAb therapy48. This evidence concerns the gene TNFRSF9 and ovarian carcinoma.